[DISCUSSION DRAFT]

112TH CONGRESS 2D SESSION	H.I	R.	
------------------------------	-----	-----------	--

To direct the Administrator of the Environmental Protection Agency to allow for the distribution, sale, and consumption in the United States of remaining inventories of over-the-counter CFC epinephrine inhalers.

IN THE HOUSE OF REPRESENTATIVES

М		introduced	the follo	owing bill	l; which	was r	referred	to	the
	Commit	tee on							

A BILL

To direct the Administrator of the Environmental Protection Agency to allow for the distribution, sale, and consumption in the United States of remaining inventories of over-the-counter CFC epinephrine inhalers.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Asthma Inhalers Relief
- 5 Act of 2012".

1	SEC. 2. DISTRIBUTION, SALE, AND CONSUMPTION OF RE-
2	MAINING INVENTORIES OF OVER-THE-
3	COUNTER CFC EPINEPHRINE INHALERS.
4	(a) In General.—The Administrator of the Envi-
5	ronmental Protection Agency—
6	(1) shall allow for the distribution, sale, and
7	consumption in the United States of remaining in-
8	ventories of CFC epinephrine inhalers manufactured
9	pursuant to the exception for medical devices under
10	section $604(d)(2)$ of the Clean Air Act (42 U.S.C.
11	7671e(d)(2));
12	(2) shall not take any enforcement action or
13	otherwise seek to restrict the distribution, sale, or
14	consumption of such inhalers on the basis of any
15	Federal law implementing the Montreal Protocol;
16	and
17	(3) shall, in response to any request of any dis-
18	tributor or seller of such inhalers, including any
19	such request pending on the date of the enactment
20	of this Act, issue a No Action Assurance Letter to
21	the requesting party stating that the Environmental
22	Protection Agency will not initiate an enforcement
23	action relating to the distribution or sale of any such
24	inhaler occurring prior to August 1, 2013.
25	(b) Rule of Construction.—Nothing in this Act
26	shall be construed to limit or otherwise affect the authority

1	of the Food and Drug Administration under the Federal
2	Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.)
3	to ensure the safety and effectiveness of CFC epinephrine
4	inhalers to be distributed, sold, or consumed pursuant to
5	this Act.
6	(c) DEFINITIONS.—In this Act:
7	(1) The term "CFC epinephrine inhaler" means
8	any epinephrine inhaler containing
9	chlorofluorocarbons that was manufactured and clas-
10	sified as over-the-counter before January 1, 2012.
11	(2) The phrase "Federal law implementing the
12	Montreal Protocol''—
13	(A) means any provision of title VI of the
14	Clean Air Act (42 U.S.C. 7671 et seq.) or other
15	Federal law implementing the Montreal Pro-
16	tocol; and
17	(B) includes the final rule published by the
18	Food and Drug Administration entitled "Use of
19	Ozone-Depleting Substances; Removal of Essen-
20	tial-Use Designation (Epinephrine)" published
21	in the Federal Register at 73 Federal Register
22	69532 (November 19, 2008).
23	(3) The term "Montreal Protocol" has the
24	meaning given such term in section 601 of the Clean
25	Air Act (42 U.S.C. 7671).

[Discussion Draft]

4

1	(4) The term "over-the-counter" means not
2	subject to section 503(b)(1) of the Federal Food,
3	Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)) or
4	otherwise required pursuant to Federal law to be
5	dispensed only upon issuance of a prescription.
6	(d) Sunset.—This section ceases to be effective Au-
7	gust 1, 2013.